CN102949299B - Application of nuciferine or plant extract containing nuciferine - Google Patents
Application of nuciferine or plant extract containing nuciferine Download PDFInfo
- Publication number
- CN102949299B CN102949299B CN201110431431.XA CN201110431431A CN102949299B CN 102949299 B CN102949299 B CN 102949299B CN 201110431431 A CN201110431431 A CN 201110431431A CN 102949299 B CN102949299 B CN 102949299B
- Authority
- CN
- China
- Prior art keywords
- nuciferine
- application
- chlosma
- dandruff
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 title claims abstract description 37
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 title claims abstract description 36
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000000419 plant extract Substances 0.000 title abstract description 8
- 208000001840 Dandruff Diseases 0.000 claims abstract description 25
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 15
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 10
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 9
- 208000017520 skin disease Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002453 shampoo Substances 0.000 claims description 7
- 206010048768 Dermatosis Diseases 0.000 claims description 6
- 206010039792 Seborrhoea Diseases 0.000 claims description 5
- 241000101040 Pityriasis Species 0.000 claims description 4
- 208000022853 pityriasis simplex Diseases 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- -1 hair conditioner Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 241000555676 Malassezia Species 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 241000555688 Malassezia furfur Species 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 241000209477 Nymphaeaceae Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000209490 Nymphaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001400675 Sympodium Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 229930014594 aporphine alkaloid Natural products 0.000 description 1
- 150000008441 aporphines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of nuciferine shown in the specification or a plant extract containing nuciferine in preparing a malassezia inhibitor. The invention further discloses an application of nuciferine or plant extract containing nuciferine in preparing medicine or daily chemical products, wherein the medicine is used for preventing and/or treating skin diseases caused by malassezia. The nuciferine has the advantages of better malassezia inhibition activity, as well as better curative effect on preventing or treating excessive scurf, seborrheic dermatitis, atopic dermatitis and psoriasis caused by the malassezia.
Description
Technical field
The present invention is specifically related to a kind of nuciferine or contains the new application of its plant extract.
Background technology
Nuciferine, English nuciferine by name, CAS number is 475-83-2, and molecular weight is 295.4, and molecular formula is C
19h
21nO
2.The method of extracting in its dried leaves from nymphaeaceae plant Flos nymphaeae (Nymphaea teragona Georgi) is the conventional method that those skilled in the art use.
Nuciferine (nuciferine) is the main chemical compositions of the dried leaves (Nelumbo nuciferaGaertn.) of Chinese medicine nymphaeaceae plant lotus.Chinese medicine is thought, Folium Nelumbinis nature and flavor bitterness is flat, returns liver, spleen, stomach, heart channel.There are the effects such as clearing away summer-heat and eliminating dampness, sending up the lucid YANG, cooling blood for hemostasis.Alkaloid in Folium Nelumbinis has medication, the dietetic therapy effects such as effect for reducing blood fat, free radical resisting, inhibition hypercholesterolemia and arteriosclerosis, but also has antimitotic effect, has stronger fungistatic effect.Nuciferine belongs to aporphine alkaloids, and its structural formula is as follows:
Chlosma is the resident flora on the mankind and homoiothermic animal skin, belongs to and has a liking for fat Basidiomycetes Saccharomyces.Before last century the nineties, people have found three kinds of chlosmas on homoiothermic animal skin, and they are respectively: Malassezia furfur, M.pachy dermats and sympodium chlosma.Then, in people's research, find that chlosma has 7 kinds, except above-mentioned 3 kinds, also have spherical chlosma, obtuse chlosma, restricted chlosma and Si Luofei chlosma.Chlosma is mainly grown in the mankind's horny layer of epidermis; it is a kind of flora of having a liking for fat; mainly taking the triacylglycerol of skin surface and free fatty acid as nutrition, be the power of sebaceous gland function and affect the principal element that triacylglycerol and free fatty secrete.Chlosma on skin stand density because of age growth with Lipid Secretion is less reduces.Chlosma is grown with mycelia mutually with Yeast Phase, and on normal human skin, with Yeast Phase growth, in 7 kinds of chlosmas, Malassezia furfur can be grown taking propylhomoserin base as intermediary separately, and other six kinds without this characteristic.Chlosma belongs to conditionality pathogenic bacterium, can cause various diseases, especially dermatosis.Therefore, in recent years its paathogenic factor had been had to research more and more widely.Quantity research shows greatly, and the dermatosis that chlosma causes is the result that has many factors comprehensive function, the generation of disease and the density of this bacterium, and strain and metabolite all have substantial connection.Quantity research shows greatly, and chlosma can cause the dandruff, seborrheic dermatitis, atopic dermatitis and psoriasis etc.
The dandruff normally naked eyes is difficult to the squama of observing, and its existence form is the unicellular form of keratinization normally, but when a certain amount of keratinization is unicellular while being attached on together, just can observe clinically the white squama of lamellar.Behrman is the scholar of first research dandruff, and he has summed up a large amount of data, by clinical manifestation, the dandruff is divided into amphitypy: pityriasis simplex type and seborrhea pityriasis type.Pityriasis simplex type is the dandruff that appears at the greyish white loose drying on normal scalp; It is many that seborrhea pityriasis type shows as squama, and greasyly easily stick, and can form wax sample crust, and substrate is red, and oozes out with a small amount of stickiness.The 25-30 layer keratinocyte that the horny layer of normal scalp has comprised complete keratinization and has mutually been close to, and in the scalp horny layer of the dandruff, be conventionally less than 10 layers of keratinocyte, and the frequent keratinization functional defect of these keratinocytes, malalinement, iuntercellular has crack.The production process of the dandruff probably start from one discontinuous, the telangiectasis in dermal papilla district.Neutrophilic granulocyte and mononuclear cell migration enter mamillary region, epidermis, cause intercellular edema of epidermis, and part necrocytosis forms phlysis, and granular layer disappears subsequently, occurs parakeratosis.In the near future, edema alleviates, the inflammatory cell mistake that fades.Epidermis self-healing, horny layer surface forms squama.
The most important microorganism relevant to the dandruff cause of disease is chlosma, the relevant theory of existing a large amount of clinical and laboratory researches.The multiple-microorganism that distributing on normal scalp, density is approximately 10
3-10
5/ mm
2, comprising staphylococcus, propionibacterium and chlosma.Chlosma in the different situation of nutritional condition, shows as Yeast Phase or mycelia phase in vivo and in vitro, and its growth has strict lipid demand.The different subtype of chlosma on molecular level can cause different inflammatory reaction and various diseases on clinical and pathology, and mycelia phase can be caused a disease with some Yeast Phase.Just have people to point out by test as far back as the sixties in 20th century, the treatment dandruff is used the curative effect of fungistat to be obviously better than bacterial inhibitor.Recently have many reports, it is too much that the oral or antifungal drug such as topical ketoconazole and ZPT can effectively be treated dandruff.
Seborrheic dermatitis is a kind of chronic skin inflammation occurring on seborrhea basis.Accompany greasy scales and incrustation as feature taking Head And Face and upper back yellowish red color patch clinically, and with obvious inflammatory reaction.Skin surface sebum increases and the change of chemical composition, makes to be present in a large amount of abnormality proliferations of normal flora of skin, causes morbidity thereby invade skin.Propose first chlosma from Malassez in 1874 relevant with the morbidity of seborrheic dermatitis, there is dispute in chlosma and seborrheic dermatitis relation always.People's confirmations such as Heng, disappearing of skin lesion is declined to become positive correlation with chlosma content.Antifungal agent is used for the treatment of after seborrheic dermatitis, and chlosma quantity obviously reduces, and skin lesion improves, and this provides strong evidence to the relation of chlosma and seborrheic dermatitis.The people such as Pechere study discovery, and the pathogenic of chlosma do not depend on its density on skin, but determined by chlosma hypotype.The people such as Tajima use round pcr analysis to show, the main bacteria seed on patient skin is spherical chlosma and restricted chlosma; And seborrheic dermatitis is relevant with the specific hypotype of restricted chlosma.
Atopic dermatitis is with pruritus, erythema, desquamation, and pachyderma is principal character.Be apt to occur in women after infant, youngster and adolescence, especially common at neck surface.Inherited genetic factors also plays an important role therein.Some documents show both at home and abroad, and in atopic dermatitis patients serum, IgE level raises.Quantity research shows greatly, and atopic dermatitis patients chlosma specific IgE antibody positive rate is 20%-100%, one of cause of disease that chlosma is atopic dermatitis.Can consider to add with antifungal agent, but need determine as the case may be when clinical practice.
Psoriasis main manifestations is the red pimple of inflammatory, and the about grain of rice is to Semen phaseoli radiati size, after be fused to gradually brownish red maculopapule and speckle, clear border, inflammatory infiltration around, the silvery white squama that surface coverage multilamellar is dry.External once report with the pityrosporum furfur of the existence of deactivation done patch experiment, can cause Pigs with Psoriasis people and rabbit body surface.Also studies have found that and in Sera in Patients with Psoriasis Vulgaris, have a kind of anti-Malassezia furfur antibody, and the soluble component of Malassezia furfur (protein) possesses obvious chemotaxis to psoriatic's M7, prompting Malassezia furfur may participate in psoriatic isomorphic response.
Summary of the invention
Technical problem to be solved by this invention has been to provide a kind of new application of nuciferine.The present invention finds that nuciferine has preferably chlosma and suppresses active, and the dandruff being caused by chlosma in prevention or treatment too much, in seborrheic dermatitis, atopic dermatitis and psoriasis, have preferably curative effect.
Therefore, the invention provides a kind of nuciferine as follows or containing its plant extract in the application of preparing in chlosma inhibitor;
The present invention also provides above-mentioned nuciferine or has prevented and/or treated the application in medicine or the daily use chemicals product of the dermatosis being caused by chlosma containing its plant extract in preparation.
Wherein, described dermatosis can be dandruff too much, atopic dermatitis, seborrheic dermatitis or psoriasis.Described dandruff too much can be pityriasis simplex type or seborrhea pityriasis type.
In the present invention, described medicine can be external preparation.Wherein, the carrier of described external preparation can comprise microsphere, liposome or microemulsion.Described external preparation can be conventional external preparation form, as spray, ointment or emulsifiable paste.
In the present invention, described daily use chemicals product can be conventional daily use chemicals product form, as shampoo, hair conditioner, cream frost, handwashing liquid, bath gel or emulsion.
In the present invention, the administering mode of described external preparation or daily use chemicals product can be through percutaneous drug delivery.
In the present invention, in described medicine or daily use chemicals product, described nuciferine or the content of plant extract containing it 0.0001%-99% that is preferably weight percentage, that better is 0.01%-5%.
Without prejudice to the field on the basis of common sense, above-mentioned each optimum condition, can combination in any, obtains the preferred embodiments of the invention.
Agents useful for same of the present invention and raw material be commercially available obtaining all.
Positive progressive effect of the present invention is: the present invention finds that nuciferine has preferably chlosma and suppresses active, and at prevention or the dandruff that caused by chlosma for the treatment of too much, in seborrheic dermatitis, atopic dermatitis and psoriasis, there is preferably curative effect.
Detailed description of the invention
Mode below by embodiment further illustrates the present invention, but does not therefore limit the present invention among described scope of embodiments.The experimental technique of unreceipted actual conditions in the following example, according to conventional method and condition, or selects according to catalogue.
Embodiment 1
The preparation of hair conditioner
Preparation technology: A is warming up to 80-85 DEG C mutually, stirs.B is warming up to 80-85 DEG C mutually, stirs.By A be added to B mutually in, homogenizing 3min.Cooling is stirred.3. be cooled to below 40 DEG C, add C phase, stir.
Embodiment 2
The preparation of shampoo
Preparation technology: deionized water is heated to 85 DEG C, and mutually each A component is added successively, stirs.Be cooled to 60-70 DEG C, add B phase, stir.Be cooled to below 40 DEG C, add C phase, stir.
Embodiment 3
The preparation of bath gel
Preparation technology: deionized water is heated to 85 DEG C, and mutually each A component is added successively, stirs.Be cooled to 60-70 DEG C, add B phase, stir.Be cooled to below 40 DEG C, add C phase, stir.
Embodiment 4
The preparation of spray
Ethanol 20%, (70%) sorbitol 10%, glycerol 5%, RH-601.5%, nuciferine 0.5%, NaF 0.03%, essence 1.0%, glucide 0.1%, benzoic acid receive 0.1%, citric acid 0.1%, deionized water surplus.
Effect embodiment 1
Below process illustrates the high bacteriostatic activity of nuciferine to chlosma by experiment.
(1) nuciferine suppresses chlosma Bactericidal test
Experimental strain: Malassezia furfur (Malassezia furfur, ATCC44344);
Culture medium: chlosma solid medium: glucose 40g/L, agar 14g/L, peptone 10g/L, distilled water dissolve, adjustings pH is 6.8-7.0,115 DEG C with condition of high voltage under sterilizing 20min; Chlosma fluid medium: glucose 40g/L, distilled water dissolves, and adjusting pH is 6.8-7.0, sterilizing 20min under 115 DEG C of condition of high voltage.
Experimental technique: tested bacterium is uploaded after culture at chlosma solid medium, guarantee purification and the vigor of bacterium colony, picking monoclonal is to 50ml chlosma fluid medium, cultivates 24h for 30 DEG C, use than turbid instrument (Biomerieux SA) adjust its to Maxwell No. 4 opacity tube concentration.With culture medium dilution bacterium liquid, making its final bacteria concentration is 10
6cFU/mL, then draws 100 μ l and is coated on solid medium, and the inhibition zone size with Oxford agar diffusion method mensuration nuciferine in the time of 1mg/ml, to judge the bacteriostatic activity of nuciferine.
Experimental result:
The inhibitory action of table 1 nuciferine to chlosma
From experiment, draw, use the nuciferine of utmost point low content just can form the inhibition zone meansigma methods larger to chlosma, good antimicrobial effect.
(2) nuciferine suppresses chlosma MIC pH-value determination pH
Experimental strain: Malassezia furfur (Malassezia furfur, ATCC44344);
Culture medium: chlosma fluid medium: glucose 40g/L, distilled water dissolves, and adjusting pH is 6.8-7.0, sterilizing 20min under 115 DEG C of condition of high voltage.
Experimental technique: tested bacterium is uploaded after culture at chlosma solid medium, to guarantee purification and the vigor of bacterium colony, picking monoclonal is to 50ml chlosma fluid medium, 30 DEG C cultivate 24h, use than turbid instrument (Biomerieux SA) adjust its to Maxwell No. 4 opacity tube concentration.Directly with chlosma fluid medium, nuciferine is diluted to experimental concentration, is respectively 100,50,25,12.5,6.25,3.125 μ g/ml.In 96 orifice-plate microporosities, add bacterium liquid 100 μ L and medicinal liquid 100 μ L, establish the normal growth contrast that does not add the negative control of bacterium and do not add medicinal liquid simultaneously, every kind of medicine do 3 parallel, average.Put 30 DEG C of wet boxes and hatch, observed result after 48h.Because chlosma is to have a liking for fat, bacterium colony floats over liquid surface, micro-yellow, and thin layer swims in transparent liquid primary surface, and perusal is very clear, adopts direct method reading out data.The prerequisite of result judgement is that growth control is good, and blank asepsis growth is clear, and with the rising of drug level gradient, the growth of bacterium is suppressed in other hole.
Experimental result
Table 2 nuciferine MIC pH-value determination pH
| Medicine (μ g/ml) | 100 | 50 | 25 | 12.5 | 6.25 | 3.125 |
| Nuciferine | - | - | - | - | + | + |
"-" represents asepsis growth; "+" representative has bacteria growing
As shown in Table 2, nuciferine is 12.5 μ g/ml to the MIC value of chlosma.
Can show that from above-mentioned two experiments the nuciferine of extremely low consumption has good fungistatic effect to chlosma.
Effect embodiment 2
Hair conditioner, shampoo prepared by above-described embodiment 1-2 are applied to clinical use research.
Tested crowd: scalp has more dandruff person 20 people, 12 male, 8 women.
Experimental technique: the hair conditioner of embodiment 1-2 and shampoo are applied to anti-dandruff experiment, within every two days, wash once head, with gently rub hair 3 minutes of shampoo, after cleaning with hair conditioner massage 5 minutes, use 10 times, after 20 days, give experimenter's application form and carry out data statistics.
Experimental result: according to experimenter's application form, carry out data statistics, the result after statistics is as follows:
| Evaluation criterion | Number | Percentage ratio |
| Cure (use after 20 days and generate without dandruff) | 4 | 20％ |
| Effectively (use dandruff after 20 days obviously to reduce) | 10 | 50％ |
| Generally (use dandruff after 20 days to have a small amount of minimizing) | 4 | 20％ |
| Without obviously changing (using after 20 days without obviously changing) | 2 | 10％ |
| Very poor (using dandruff after 20 days to get more and more) | 0 | 0％ |
Carry out clinical use 20 days being applied in the too much crowd of dandruff, improvement rate exceedes 70%, and the shampoo that therefore prepared by embodiment and surfactant have good inhibition dandruff and generate effect.
Claims (8)
1. nuciferine as follows prevents and/or treats the application in medicine or the daily use chemicals product of the dermatosis being caused by chlosma in preparation, it is characterized in that: described dermatosis be dandruff too much, atopic dermatitis, seborrheic dermatitis or psoriasis;
2. application as claimed in claim 1, is characterized in that: described dandruff is crossed pityriasis simplex type or the seborrhea pityriasis type of mostly being.
3. application as claimed in claim 1 or 2, is characterized in that: described medicine is external preparation.
4. application as claimed in claim 3, is characterized in that: the carrier of described external preparation comprises microsphere, liposome or microemulsion.
5. application as claimed in claim 3, is characterized in that: described external preparation is spray, ointment or emulsifiable paste.
6. application as claimed in claim 1 or 2, is characterized in that: described daily use chemicals product are shampoo, hair conditioner, cream frost, handwashing liquid, bath gel or emulsion.
7. application as claimed in claim 1 or 2, is characterized in that: in described medicine or daily use chemicals product, and the content of the described nuciferine 0.0001%-99% that is weight percentage.
8. application as claimed in claim 7, is characterized in that: in described medicine or daily use chemicals product, the content of described nuciferine is weight percentage as 0.01%-5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110431431.XA CN102949299B (en) | 2011-12-20 | 2011-12-20 | Application of nuciferine or plant extract containing nuciferine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110431431.XA CN102949299B (en) | 2011-12-20 | 2011-12-20 | Application of nuciferine or plant extract containing nuciferine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102949299A CN102949299A (en) | 2013-03-06 |
| CN102949299B true CN102949299B (en) | 2014-08-06 |
Family
ID=47759060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110431431.XA Active CN102949299B (en) | 2011-12-20 | 2011-12-20 | Application of nuciferine or plant extract containing nuciferine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102949299B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520114B (en) * | 2013-09-22 | 2015-05-13 | 武汉大学 | Nuciferine microsphere and preparation method thereof |
| CN105640836B (en) * | 2016-02-03 | 2019-05-14 | 重庆菩璞生物科技有限公司 | A kind of surfactant and preparation method thereof containing lotus active constituent |
| CN105796416B (en) * | 2016-03-22 | 2019-01-04 | 广东嘉丹婷日用品有限公司 | A kind of lasting smooth skin care composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001199862A (en) * | 2000-01-14 | 2001-07-24 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing moisture retention plant extract |
| US8277852B2 (en) * | 2002-01-25 | 2012-10-02 | Akzo Nobel Surface Chemistry Llc | Bioactive botanical cosmetic compositions and processes for their production |
| DE102006062438A1 (en) * | 2006-12-27 | 2008-07-03 | Henkel Kgaa | Cosmetic or dermatological composition, useful e.g. in the topical treatment of the skin, comprises an aporphine-alkaloids and a further active agent of e.g. purine, natural betaine compounds, monomer, oligomer or polymer of aminoacid |
| CN101869542B (en) * | 2009-04-24 | 2012-07-04 | 湖北中烟工业有限责任公司 | Toner comprising pawpaw extract and lotus leaf extract and preparation method thereof |
-
2011
- 2011-12-20 CN CN201110431431.XA patent/CN102949299B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102949299A (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102218048B (en) | Application of magnolol in preparation of external preparations and daily chemical products for treating dermatosis caused by malassezia | |
| Leeming et al. | The distribution and ecology of Malassezia furfur and cutaneous bacteria on human skin | |
| CN105250189B (en) | A kind of anti-acne maintenance essence cream and preparation method thereof | |
| JP6033435B2 (en) | Antibacterial composition containing a phyllobasidium inhibitor derived from a natural product | |
| CN102526019B (en) | Use of usnic acid and derivatives of usnic acid for preparation of medicaments for treating skin diseases caused by malassezia | |
| CN102949460A (en) | Application of melaleuca alternifolia oil and preparation thereof | |
| CN107233236A (en) | A kind of fair-skinned bright fine flour frost and preparation method thereof | |
| CN102949405A (en) | Application of tea saponin and preparation thereof | |
| CN109431914A (en) | Scalp care composition and application thereof | |
| CN102949299B (en) | Application of nuciferine or plant extract containing nuciferine | |
| WO2020132930A1 (en) | Anti-dandruff anti-itch shampoo composition containing multiple-component zinc | |
| CN113940907B (en) | Anti-dandruff composition containing synergistic antibacterial components and application thereof | |
| WO2017197688A1 (en) | Human body cleaning agent and preparation method therefor | |
| CN101507759B (en) | Traditional Chinese medicine combination capable of preventing and treating seborrheic dermatitis and preparation and preparation method thereof | |
| CN115337233B (en) | Gel mask with mild acne removing effect and preparation method thereof | |
| KR101598083B1 (en) | An antifungal composition comprising an natural fermentation material | |
| CN104287982A (en) | Dandruff removal composition for adjusting oil balance of scalp | |
| CN102949429B (en) | Applications of tea seed flavonoid glycoside and preparation of tea seed flavonoid glycoside | |
| KR102254553B1 (en) | Lactobacillus paracasei HY7015 having hair growth promotion, and a composition for promoting hair growth containing there of as effective component | |
| CN104887600A (en) | Living cell anti-wrinkling mask | |
| CN110201044A (en) | Chinese rose extract, containing its product and its preparation method and application | |
| CN117298198B (en) | Microalgae extract and application thereof | |
| CN108938540A (en) | A kind of brilliant profit mildy wash | |
| KR101078595B1 (en) | Hair Cosmetic Composition for Anti-Dandruff, Preventing the Hair Loss and Promoting the Hair Growth Comprising Phaseolus radiatus extracts by Fermentation and Enzyme Treatment | |
| CN106176523A (en) | For making compositions of essence containing yak milk composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: LB NATURE (SHANGHAI) CO., LTD. Free format text: FORMER NAME: SHANGHAI LAIBO BIO-CHEMICAL CO. LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 200233, room 2, building 500, No. 109, Xuhui District, Shanghai, Caobao Road Patentee after: Laibo Industrial (Shanghai) Limited by Share Ltd Address before: 200233, room 2, building 500, No. 109, Xuhui District, Shanghai, Caobao Road Patentee before: Shanghai Laibo Bio-chemical Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 200233, room 8, building 1, building 333, No. 701, Guiping Road, Shanghai, Xuhui District Patentee after: Laibo cosmeceutical Technology (Shanghai) Limited by Share Ltd Address before: 200233, room 2, building 500, No. 109, Xuhui District, Shanghai, Caobao Road Patentee before: Laibo Industrial (Shanghai) Limited by Share Ltd |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191008 Address after: 201404 workshop 1, building 4, No. 666, Jinbi Road, Jinhui Town, Fengxian District, Shanghai Patentee after: Shanghai Sheng Wei Biological Technology Co., Ltd. Address before: 200233, room 8, building 1, building 333, No. 701, Guiping Road, Shanghai, Xuhui District Patentee before: Laibo cosmeceutical Technology (Shanghai) Limited by Share Ltd |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 201404 workshop 1, building 4, No. 666, Jinbi Road, Jinhui Town, Fengxian District, Shanghai Patentee after: Shanghai Zhina Biotechnology Co.,Ltd. Address before: 201404 workshop 1, building 4, No. 666, Jinbi Road, Jinhui Town, Fengxian District, Shanghai Patentee before: SHANGHAI SHENGWEI BIOLOGICAL TECHNOLOGY Co.,Ltd. |